Doravirine 100 mg
Product Overview
| Generic Name | Doravirine 100 mg |
| Brand Name(s) | Pifeltro® |
| Category | Antivirals - Antiretrovirals |
| Form | 30 Film‑coated oral tablets |
| Strength | 100mg Tablets |
| Therapeutic Class | Non‑nucleoside reverse transcriptase inhibitor (NNRTI) |
| ATC Code | J05AG06 |
Manufacturing & Regulatory
| Manufacturer | Merck & Co (developer & manufacturer of Pifeltro) |
| GMP Compliance | WHO-GMP |
| DMF/CEP | Type II |
| COFEPRIS | Pending |
| Free Sale Certificate | Yes |
Logistics & Export
| MOQ | 10 pks |
| Shelf Life | 24 Months |
| Storage | Store below 25 °C; protect from moisture/light |
| Incoterms | EXW/FOB/CIF negotiable |
| Lead Time | 7 - 10 Business Days |
Documentation Available Upon Request
| Certificate of Analysis (PDF) | Provided per batch |
| SDS-Safety Data Sheet (PDF) | Available from manufacturer |
| CTD Summary (PDF) | Upon Request |
Special Notes
Indications & Usage: Doravirine is an NNRTI indicated for the treatment of HIV‑1 infection in treatment-naïve adults and in regimen-switch patients with virologic suppression (<50 copies/mL). It’s administered once daily (100 mg) with or without food and typically used in combination with other ARVs. Doravirine avoids common NNRTI resistance mutations and has fewer drug–drug interactions.